AOD-9604

AOD-9604 is a synthetic peptide fragment of human growth hormone (hGH 177-191). It was developed by Metabolic Pharmaceuticals to capture the fat-burning properties of GH without the side effects of full-length GH (insulin resistance, water retention, IGF-1 elevation). It stimulates lipolysis in adipose tissue and inhibits new fat production.

Full-length HGH stimulates muscle growth, fat loss, and IGF-1 production — but also causes insulin resistance, water retention, and potential proliferative effects. AOD-9604 targets only the fat metabolism pathway, producing lipolysis without significant IGF-1 elevation, anabolic effects, or carbohydrate metabolism disruption. This makes it a cleaner fat loss research tool.

AOD-9604 is not FDA approved. It received Generally Recognized as Safe (GRAS) status for use as a food ingredient in 2014. It previously went through clinical trials for obesity treatment but did not achieve the required efficacy threshold in Phase 3 trials for oral formulation, though injectable forms continue as research subjects.

AOD-9604 and GLP-1 agonists like retatrutide or tirzepatide operate through entirely different mechanisms — GH fragment lipolysis vs. incretin receptor agonism. There is no known negative interaction. Some researchers combine them for complementary fat loss pathways: GLP-1 agonists address appetite and metabolic rate; AOD-9604 targets adipocyte lipolysis directly.

Research protocols typically use 300-500 mcg subcutaneously once daily, often in a fasted state in the morning or pre-workout to maximize lipolytic activity. The peptide has a short action window and is typically administered 30 minutes before physical activity or food intake in protocol designs.